Gynecologic cancers remain a major global health burden, particularly in low- and middle-income countries, with high incidence and mortality rates around 45–50%. The detection of minimal residual disease (MRD) is transforming the management of recurrence risk in gynecologic cancers through highly sensitive molecular technologies. MRD encompasses small populations of residual cancer cells or post-treatment molecular traces but remain undetectable by conventional methods. Its detection relies on circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and advanced next-generation sequencing (NGS), with ctDNA-based MRD assays having sensitivity levels between 85% and over 99%. Other technologies, such as liquid biopsies and digital PCR, are also in development. MRD status has demonstrated high predictors of recurrence and survival with positive MRD strongly associated with poor outcomes and negative MRD indicates sustained remission. However, MRD detection faces significant limitations, such as tumor heterogeneity, inconstant ctDNA levels, technical issues of false-negative results, and limited clinical accessibility. Therefore, this review presents current evidence regarding the molecular detection of MRD in gynecologic malignancies and assesses its prognostic and predictive relevance. Ultimately, MRD continuous integration into clinical practice offers a promising modality to enable early relapse detection, more precise therapeutic decision-making, and the improvement of personalized medicine access to gynecologic cancers worldwide.

Introduction: Breast cancer remains a prevalent global malignancy and necessitates a treatment regimen, which is often accompanied by substantial side effects. To address this challenge, alternative therapies with fewer adverse effects are urgently needed. Amomum cardamomum has displayed promising anticancer potential. This study aimed to investigate the impact of A. cardamomum seed on T47D breast cancer cell viability and the ability to induce apoptosis, utilizing in silico and in vitro approaches. Methods: The samples were extracted utilizing the maceration method using ethanol 96% solvent. In addition, the bioactive constituents were identified through phytochemicals and GC/MS analysis. Cell viability was assessed through MTT assay at various concentrations with 24 and 48-hour incubation periods and compared with the control cells. Apoptosis patterns were visualized by Immunofluorescence assay and analyzed utilizing ImageJ software. In silico analyses included three distinct tests, namely pharmacokinetics analysis (ADMET), bioactivity prediction (PASS), and molecular docking. Results: The A. cardamomum seed extract inhibited the growth of the cells with an IC50 value of 97.28 μg/mL in 48 hours of the incubation period. Immunofluorescence assay exhibited that the extract induced apoptosis in over 50% of T47D cells. In silico approaches identified bicyclogermacrene, Germacrene-D, and δ-cadinene as potential JAK3, BRAF v600e, and MMP9 protein inhibitors. These compounds exhibited stronger binding affinities to critical amino acids than control ligands. Conclusion: This research presents compelling evidence that the A. cardamomum extract has anticancer activity against breast cancer by preventing growth and inducing apoptosis.

Context: Plasmodium knowlesi is an emerging zoonotic malaria species in Southeast Asia, challenging elimination efforts. Aims: To design a safe and immunogenic multi-epitope vaccine (MEV) targeting the merozoite surface protein-1 (MSP-1) of P. knowlesi using a comprehensive immunoinformatics approach. Methods: Conserved regions of the P. knowlesi MSP-1 sequence were retrieved and analyzed to predict helper T lymphocyte (HTL), cytotoxic T lymphocyte (CTL), and B cell epitopes. Epitopes were selected based on predicted immunogenicity, solubility, and safety. Suitable linkers were used to fuse selected epitopes, adjuvants, and sequences into a multi-epitope vaccine (MEV) construct. Physicochemical properties, immunogenicity, allergenicity, and antigenicity of the MEV were assessed in silico. Molecular docking and molecular dynamics (MD) simulation were conducted to evaluate MEV binding affinity and stability with toll-like receptor 4 (TLR4). The immunogenic potential was further evaluated using the C-ImmSim server to simulate host immune responses. Results: The 219-amino acid MEV construct was predicted to be stable, soluble, non-toxic, and non-allergenic, with 98.89% global population coverage. Molecular docking and MD simulations confirmed a stable interaction with TLR4. Immune simulation revealed efficient antigen clearance, significant production of IgM and IgG1/IgG2 antibodies, expansion of plasma and memory B cells, and activation of CD4⁺ and CD8⁺ T cells. A Th1-skewed cytokine response was observed, marked by elevated IFN-γ, IL-2, and IL-12 levels. Conclusions: The in silico-designed MEV demonstrated favorable immunological, structural, and population coverage profiles, supporting its potential as a promising vaccine candidate against P. knowlesi malaria. Further experimental validation is needed.

Cervical cancer remains one of the most lethal cancers affecting women, with infection by high-risk Human Papillomavirus (HR-HPV), especially HPV-16, recognized as a primary cause. Phyllanthus urinaria, a plant that grows in Indonesia, has demonstrated notable both antiviral and anticancer properties. This study aimed to investigate the potential of P. urinaria as both an antiviral and anti-cervical cancer agent. The HPV-16 E6 protein was modeled using homology modelling, with model accuracy verified through torsional angle assessment and identification of conserved regions. Molecular docking was performed to examine E6–p53 interactions. Fraction of n-hexane compounds of P. urinaria were further evaluated for their interaction with E6 by molecular docking and molecular dynamics simulation. Additionally, in vitro cytotoxicity assays were conducted using HaCaT (normal keratinocyte) and HeLa (cervical cancer) cell lines. Compounds from P. urinaria were found to interact with E6 within conserved regions and these interactions were more stable conformationally than those observed for p53. In vitro assay demonstrated that P. urinaria exhibited moderate cytotoxicity against HeLa cells but had limited toxicity toward HaCaT cells. The n-hexane fraction of P. urinaria leaves exhibits anti-cervical cancer activity by inhibiting HPV-16 E6 and eliminating cervical cancer cells.

Background: Hemorrhagic wounds pose significant clinical challenges, with approximately 20% associated with surgical site infections and an increased mortality risk. Despite growing interest in natural product-based medicines, the molecular targets and bioactive phytochemicals of Musa acuminata peel relevant to hemorrhagic wound healing are insufficiently established. Methods: This study employed an integrative in silico approach to identify bioactive phytochemicals from the ethyl acetate extract of Musa acuminata peel as potential wound healing agents. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) profiling was performed for phytochemical characterization, followed by drug-likeness and toxicity screening via OSIRIS DataWarrior. Network pharmacology, molecular docking, molecular dynamics (MD), binding free energy calculation, pharmacokinetic properties prediction, and density functional theory (DFT) analysis were subsequently conducted. Results: LC–HRMS profiling identified 211 compounds across 21 chemical classes, of which 18 met drug-likeness criteria. Network pharmacology revealed five key protein targets. Molecular docking demonstrated that Compound 16 (−9.34 kcal/mol) and Compound 17 (−9.26 kcal/mol) exhibited stronger binding affinity toward VEGFR2 than Axitinib (−9.15 kcal/mol), with key interactions at glutamic acid-917 (GLU917) and cysteine-919 (CYS919). MD simulations over 100 ns confirmed complex stability, with BP16 showing superior binding stability and favorable MM/PBSA free energy. Pharmacokinetics and DFT analysis further supported BP16 as the most promising lead compound, exhibiting favorable pharmacokinetic properties, low predicted toxicity, and enhanced electronic stability. Conclusions: BP16 and BP17 are identified as potential VEGFR2-targeting candidates, providing a rational mechanistic foundation for future experimental validation as natural hemorrhagic wound healing therapeutics.

Background Breast cancer remains one of the leading causes of cancer-related mortality worldwide, and the emergence of drug resistance, systemic toxicity, and limited efficacy of current therapies highlight the need for safer and more effective treatment. Natural products have emerged as promising sources of multi-target anticancer agents. A. cardamomum has demonstrated preliminary anticancer potential, yet the bioactive constituents and their molecular mechanisms in breast cancer remain poorly elucidated. Methods This study integrated in silico approaches to investigate the therapeutic potential of A. cardamomum seed extract against breast cancer. LC–MS analysis identified phytochemical compounds, followed by network pharmacology to determine their potential targets and molecular pathways. Pharmacokinetic and toxicity predictions were assessed through ADMET and Lipinski’s rule of five analyses to evaluate drug-likeness and safety. Molecular docking and molecular dynamics (MD) simulations were conducted to evaluate binding affinity and structural stability of compounds with key oncogenic proteins. Results LC-MS profiling identified 22 distinct compounds in A. cardamomum seeds. ADMET and Lipinski analyses demonstrated that most compounds possessed high gastrointestinal absorption, favorable oral bioavailability, and low toxicity risk. Network pharmacology highlighting SRC, TNF-α, Caspase-3, and EGFR as central nodes in the protein-protein interaction network. Molecular docking identified compounds C17 and C20 as the most promising bioactives, showing strong binding affinities and interactions similar to control ligands. MD simulations confirmed their stable complexes, indicating conformational stability and robust ligand–protein interactions. Conclusion This study highlights the promising multi-target anticancer potential of A. cardamomum seeds. Compounds C17 and C20 were identified as lead candidates with strong and stable interactions with key breast cancer-related proteins and favorable pharmacokinetic properties. These results suggest that A. cardamomum could serve as a potential source for developing new plant-based therapies against breast cancer. Further in vitro and in vivo investigations are warranted to validate their efficacy and safety.